Herceptin (trastuzumab) - Important Safety Information from Roche Products (Ireland) Ltd. as approved by the HPRA

Notice type: 3rd Party Publications

Date: 22/03/2017


Problem Or Issue:
Important Safety Information communication from Roche Products (Ireland) Ltd. - Herceptin (trastuzumab): Reminder of importance of cardiac monitoring guidance during trastuzumab therapy to reduce the frequency and severity of left ventricular dysfunction and congestive heart failure (CHF).

« Back